Kadmon Holdings Inc (NYSE:KDMN) – Jefferies Group reduced their FY2017 earnings per share estimates for Kadmon in a note issued to investors on Wednesday. Jefferies Group analyst B. Amin now expects that the company will earn ($1.73) per share for the year, down from their previous estimate of ($1.71). Jefferies Group also issued estimates for Kadmon’s Q4 2017 earnings at ($0.47) EPS, Q4 2018 earnings at ($0.53) EPS, FY2018 earnings at ($2.09) EPS, FY2019 earnings at ($2.42) EPS, FY2020 earnings at ($2.56) EPS and FY2021 earnings at ($2.82) EPS.
Kadmon (NYSE:KDMN) last posted its earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million for the quarter, compared to the consensus estimate of $5.69 million. During the same period last year, the firm earned ($4.24) earnings per share. The business’s quarterly revenue was down 60.0% compared to the same quarter last year.
Kadmon (KDMN) opened at $3.51 on Monday. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.60. The company has a market cap of $279.97, a price-to-earnings ratio of -2.01 and a beta of 2.58.
Several large investors have recently bought and sold shares of KDMN. Sphera Funds Management LTD. bought a new stake in shares of Kadmon in the 3rd quarter valued at about $3,685,000. Vanguard Group Inc. raised its holdings in shares of Kadmon by 166.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock valued at $5,870,000 after purchasing an additional 941,549 shares in the last quarter. Crestline Management LP bought a new stake in shares of Kadmon in the 3rd quarter valued at about $2,011,000. Sabby Management LLC purchased a new position in shares of Kadmon in the 2nd quarter worth approximately $2,112,000. Finally, Susquehanna International Group LLP grew its position in shares of Kadmon by 3,211.2% in the 3rd quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock worth $1,485,000 after buying an additional 429,752 shares during the last quarter. Institutional investors and hedge funds own 51.90% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.